Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edaravone oral - Treeway

Next Previous
Search
Drug Profile

Edaravone oral - Treeway

Alternative Names: FAB-122; FNP-122; TW-001; TW-101

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Treeway
  • Developer Ferrer; Treeway
  • Class Anti-ischaemics; Antidementias; Antihaemorrhagics; Antiparkinsonians; Hepatoprotectants; Neuroprotectants; Pyrazolones; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis
  • Phase II Alzheimer's disease

Most Recent Events

  • 01 Mar 2025 Treeway completes the phase II ASURE trial in Alzheimer's disease in Croatia, Netherlands (PO) (NCT05323812) ((700350992)
  • 30 Dec 2024 Treeway completes the phase II ASURE trial in Alzheimer's disease in Bulgaria (PO) (EudraCT2021-003164-27)
  • 22 Feb 2024 Ferrer terminates the phase III ADOREXT trial in Amyotrophic lateral sclerosis in Spain, Italy, France, Belgium, Germany, the Netherlands, Poland, Ireland and Sweden due to lack of efficacy of Edaravone (NCT05866926) (EudraCT2022-003050-32)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top